OCGN - NASDAQ

Ocugen, Inc.

OCGN·NASDAQ

$1.34

-5.1%

HealthcareBiotechnology

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$453.62M

EPS-0.2300

P/E Ratio-5.97

Earnings Date07/30/2026

ocgn

Cash at Beginning of Period

Last Annual Value

58.82M

3-Year CAGR

-15%

5-Year CAGR

51%

10-Year CAGR

Adjust for Inflation

Ocugen, Inc. Competitors Analysis of Cash at Beginning of Period

OCGN · NASDAQ

Company	Cash at Beginning of Period	CAGR 3Y	CAGR 5Y	CAGR 10Y
Ocugen, Inc. NASDAQ:OCGN	58.82M	-8.8%	19.4%	6.6%
Compass Therapeutics, Inc. NASDAQ:CMPX	44.05M	8.0%	-1.4%	N/A
Alumis Inc. Common Stock NASDAQ:ALMS	170.63M	85.0%	N/A	N/A
Lineage Cell Therapeutics, Inc. AMEX:LCTX	46.35M	57.2%	6.9%	0.9%
Neurogene Inc. NASDAQ:NGNE	136.93M	18.6%	10.2%	13.2%
Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA	143.36M	-16.0%	-5.7%	N/A
Omeros Corporation NASDAQ:OMER	3.40M	-32.4%	-20.2%	9.6%
Fulcrum Therapeutics, Inc. NASDAQ:FULC	59.41M	18.0%	0.4%	N/A
RAPT Therapeutics, Inc. NASDAQ:RAPT	47.48M	6.8%	13.8%	N/A
Lexicon Pharmaceuticals, Inc. NASDAQ:LXRX	66.66M	12.9%	-12.0%	-10.5%

Ocugen, Inc. Fair Value Envelope

OCGN · NASDAQ

Our analysis suggests that OCGN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.34, this represents a potential HIDDEN relative to our calculated worth for Ocugen, Inc..

HIDDEN

Intrinsic Value

Current Price: $1.34

Related Guides

Blog Categories

Continue your OCGN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.